» Articles » PMID: 4364408

Human Platelet Collagenase

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1974 Jun 1
PMID 4364408
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The presence of proteolytic enzymes such as cathepsin and elastase in platelets and the important role of collagen in platelet aggregation suggested that collagenase might be present in platelets. Epinephrine, ADP, and collagen liberate collagenase from platelets in plasma as measured by the hydrolysis of [(14)C]glycine-labeled collagen fibrils. The collagenase activity appeared in an early phase of platelet aggregation and was not a part of the release reaction. However, only 50% of the total collagenase could be liberated by the aggregating agents used. Sucrose density gradient analysis of platelet homogenates using appropriate sub-cellular markers indicated that collagenase appeared in both the granule and membrane fractions. Gel-filtered platelets failed to show collagenase activity before exposure to aggregating agents but released more collagenolytic activity than was found in platelet-rich plasma. This observation was explained by the finding that collagenolytic activity was inhibited by normal human plasma. One of the inhibitors is alpha(1)-antitrypsin as demonstrated by decreased inhibition in plasma from a patient with homozygous alpha(1)-antitrypsin deficiency. Platelet collagenase activity could also be demonstrated by its ability to decrease the viscosity of collagen solutions and to produce collagen fragments similar to those produced by other mammalian collagenases on disk gel electrophoresis. The observation that partially purified platelet collagenase could destroy the platelet-aggregating activity of collagen suggests that the enzyme might function in a negative feedback mechanism limiting thrombus formation.

Citing Articles

Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes.

Oncul S, Cho M Cancers (Basel). 2023; 15(4).

PMID: 36831623 PMC: 9953912. DOI: 10.3390/cancers15041282.


Platelets and Their Interactions with Other Immune Cells.

Lam F, Vijayan K, Rumbaut R Compr Physiol. 2015; 5(3):1265-80.

PMID: 26140718 PMC: 4510953. DOI: 10.1002/cphy.c140074.


Trypsin causes platelet activation independently of known protease-activated receptors.

Mao Y, Kunapuli S Thromb Haemost. 2013; 110(6):1241-9.

PMID: 24030758 PMC: 4077195. DOI: 10.1160/TH13-03-0189.


Matrix metalloproteases and PAR1 activation.

Austin K, Covic L, Kuliopulos A Blood. 2012; 121(3):431-9.

PMID: 23086754 PMC: 3548166. DOI: 10.1182/blood-2012-09-355958.


Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site.

Trivedi V, Boire A, Tchernychev B, Kaneider N, Leger A, OCallaghan K Cell. 2009; 137(2):332-43.

PMID: 19379698 PMC: 2807741. DOI: 10.1016/j.cell.2009.02.018.


References
1.
Kassell B, Kay J . Zymogens of proteolytic enzymes. Science. 1973; 180(4090):1022-7. DOI: 10.1126/science.180.4090.1022. View

2.
Dixon T, PURDOM M . Serum 5-nucleotidase. J Clin Pathol. 1954; 7(4):341-3. PMC: 1023849. DOI: 10.1136/jcp.7.4.341. View

3.
White J . Effects of ethylenediamine tetracetic acid (EDTA) on platelet structure. Scand J Haematol. 1968; 5(4):241-54. DOI: 10.1111/j.1600-0609.1968.tb01743.x. View

4.
Wilner G, Nossel H, LeRoy E . Aggregation of platelets by collagen. J Clin Invest. 1968; 47(12):2616-21. PMC: 297432. DOI: 10.1172/JCI105944. View

5.
KOCSIS J, Hernandovich J, Silver M, Smith J, Ingerman C . Duration of inhibition of platelet prostaglandin formation and aggregation by ingested aspirin or indomethacin. Prostaglandins. 1973; 3(2):141-4. DOI: 10.1016/0090-6980(73)90081-6. View